MethylGene, Otsuka Pharmaceutical deal

Otsuka made a US$1.5 million equity investment in MethylGene under a 2008 deal to develop and commercialize kinase inhibitors for ocular diseases, excluding cancer. Originally, Otsuka agreed to make a...